A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)

PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

August 31, 2005

Study Completion Date

June 30, 2006

Conditions
Anxiety Disorders
Interventions
DRUG

PRX-00023

Trial Locations (20)

10029

Mount Sinai School of Medicine, New York

19140

Unversity of Pennsylvania, Philadelphia

20037

The George Washington University, Washington D.C.

22041

Comprehensive Neurosciences, Falls Church

25301

Sidney Lerfald, MD, Charleston

30060

Northwest Behavioral Research, Marietta

30328

Atlanta Institute of Research and Medicine, Atlanta

33912

Gulf Coast Clinical Research Center, Fort Myers

48073

Pivotal Research Center, Royal Oak

70114

Louisiana Research Associates, New Orleans

75235

UT Southwestern Medical Center, Dallas

78756

Future Search Trials, Austin

85206

Vista Medical Research, Mesa

85210

Pivotal Research Center, Mesa

91739

Pacific Clinical Research Group, Upland

92801

Anaheim Research Center, Anaheim

97210

Oregon Center for Clinical Investigations, Portland

97301

Oregon Center for Clinical Investigations, Salem

06416

Connecticut Clinical Research, Cromwell

07033

Comprehensive Neurosciences, Kenilworth

Sponsors
All Listed Sponsors
lead

Epix Pharmaceuticals, Inc.

INDUSTRY